-
公开(公告)号：WO2012145382A2
公开(公告)日：2012-10-26
申请号：PCT/US2012/034049
申请日：2012-04-18
Applicant: TRAXXSSON, LLC , PUSKAS, Robert , HELD, Douglas
Inventor： PUSKAS, Robert , HELD, Douglas
CPC classification number: G01N33/57488 , C12Q1/485 , G01N33/57407 , G01N2333/91205 , G01N2800/52 , G01N2800/56
Abstract: A method for characterizing a carcinoma in a subject. The method comprises assaying a sample of a bodily fluid derived from the subject for extracellular PKA activity and comparing the activity to a reference value. In the assay, a reaction mixture is prepared comprising the previously unfrozen sample, a PKA peptide substrate, a phosphorylation agent, the prepared mixture is incubated, and phosphorylated substrate formed in the incubated mixture is detected. The reference value is the amount of phosphorylated substrate formed in a mixture under equivalent redox conditions for a sample of bodily fluid derived from a population of normal subjects of the same species.
Abstract translation: 用于表征受试者中癌症的方法。 该方法包括测定来源于受试者的体液样品的细胞外PKA活性，并将该活性与参考值进行比较。 在测定中，制备包含先前未冻结的样品，PKA肽底物，磷酸化剂的反应混合物，将所制备的混合物孵育，并检测在培养的混合物中形成的磷酸化底物。 参考值是在等同的氧化还原条件下在来自相同物种的正常受试者群体的体液样品中在混合物中形成的磷酸化底物的量。
-
公开(公告)号：WO2012034061A9
公开(公告)日：2012-06-28
申请号：PCT/US2011051067
申请日：2011-09-09
Applicant: TRAXXSSON LLC , PUSKAS ROBERT , HELD DOUGLAS
Inventor： PUSKAS ROBERT , HELD DOUGLAS
IPC: G01N33/574 , C12Q1/68 , G01N33/68
CPC classification number: G01N33/6875 , G01N33/57407 , G01N2333/75 , G01N2333/91205
Abstract: The present disclosure relates to methods for determining the presence, activity, and/or concentrations of certain cancer biomarkers and their use in determining the presence of cancer.
-
公开(公告)号：WO2009126380A3
公开(公告)日：2009-12-03
申请号：PCT/US2009036086
申请日：2009-03-04
Applicant: SINGULEX INC , GOIX PHILIPPE J , PUSKAS ROBERT , TODD JOHN , LIVINGSTON RICHARD A , HELD DOUGLAS , AGEE SARA
Inventor： GOIX PHILIPPE J , PUSKAS ROBERT , TODD JOHN , LIVINGSTON RICHARD A , HELD DOUGLAS , AGEE SARA
IPC: G01N33/53
CPC classification number: G01N33/577 , A61B5/00 , A61B5/0402 , A61B5/412 , A61B5/415 , A61B5/418 , A61B5/7264 , A61B5/7275 , G01N21/6428 , G01N33/582 , G01N33/6863 , G01N33/6869 , G01N33/6872 , G01N33/6887 , G01N33/6896 , G01N33/74 , G01N33/92 , G01N2333/4712 , G01N2333/475 , Y02A90/26 , Y10T436/143333
Abstract: The present invention discloses methods for the detection and monitoring of a condition in a subject using highly sensitive detection of molecules. The invention provides a method for detecting or monitoring a condition in a subject, comprising detecting a first marker in a first sample from the subject and detecting a second marker, wherein the first marker comprises a biomarker, e.g., Cardiac Troponin-I (cTnl) or Vascular Endothelial Growth Factor (VEGF), and wherein the limit of detection of the first marker is less than about 10 pg/ml. The second marker can be a biomarker, physiological marker, a molecular marker or a genetic marker.
Abstract translation: 本发明公开了使用分子的高灵敏度检测来检测和监测受试者状况的方法。 本发明提供了用于检测或监测受试者状况的方法，包括检测来自受试者的第一样品中的第一标志物和检测第二标志物，其中第一标志物包含生物标志物，例如心脏肌钙蛋白-I（cTnI） 或血管内皮生长因子（VEGF），并且其中第一标记的检测极限小于约10pg / ml。 第二个标记可以是生物标记，生理标记，分子标记或遗传标记。
-
公开(公告)号：WO2006036182A2
公开(公告)日：2006-04-06
申请号：PCT/US2005003524
申请日：2005-01-28
Applicant: SINGULEX INC , PUSKAS ROBERT , GIOX PHILIPPE , LIVINGSTON RICHARD A , HELD DOUGLAS D , KLEIN BARBARA , FUKUSHIMA NOELLE , FREESE ROBERT , DAVID PETER , URDEA MICKEY
Inventor： PUSKAS ROBERT , GIOX PHILIPPE , LIVINGSTON RICHARD A , HELD DOUGLAS D , KLEIN BARBARA , FUKUSHIMA NOELLE , FREESE ROBERT , DAVID PETER , URDEA MICKEY
IPC: G01N24/00
CPC classification number: G01N35/1095 , G01N1/28 , G01N15/1459 , G01N21/6428 , G01N27/447 , G01N33/68 , G01N33/6803 , G01N33/6845 , G01N2015/1438 , G01N2035/1034
Abstract: The invention encompasses analyzers and analyzer systems that include a single particle analyzer, methods of using the analyzers and analyzers systems to analyze samples, either for single particles of for multiple particles (multiplexing), methods of doing business based on the use of the analyzers or analyzer systems of the system, and electronic media for storing parameters useful in the analyzers and analyzer systems of the invention.
Abstract translation: 本发明包括分析器和分析器系统，其包括单个粒子分析器，使用分析器和分析器系统分析样品的方法，用于多个粒子的单个粒子（复用），基于使用分析器的业务方法或 系统的分析器系统和用于存储在本发明的分析器和分析器系统中有用的参数的电子介质。
-
公开(公告)号：WO2012145399A3
公开(公告)日：2013-01-24
申请号：PCT/US2012034080
申请日：2012-04-18
Applicant: TRAXXSSON LLC , PUSKAS ROBERT , HELD DOUGLAS
Inventor： PUSKAS ROBERT , HELD DOUGLAS
IPC: G01N33/574 , C12Q1/48 , G01N33/68
CPC classification number: C12Q1/6886 , G01N33/57419 , G01N33/57423 , G01N33/57434 , G01N33/57438 , G01N33/57449 , G01N33/57488 , G01N33/57496
Abstract: The present disclosure relates to methods for determining the presence, activity, and/or concentrations of certain cancer biomarkers and their use in determining the presence of cancer.
Abstract translation: 本公开涉及用于确定某些癌症生物标志物的存在，活性和/或浓度及其在确定癌症存在中的用途的方法。
-
Patent Agency Ranking
公开(公告)号：WO2012034061A2
公开(公告)日：2012-03-15
申请号：PCT/US2011/051067
申请日：2011-09-09
Applicant: TRAXXSSON, LLC , PUSKAS, Robert , HELD, Douglas
Inventor： PUSKAS, Robert , HELD, Douglas
IPC: G01N33/574 , G01N33/68 , C12Q1/68
CPC classification number: G01N33/6875 , G01N33/57407 , G01N2333/75 , G01N2333/91205
Abstract: The present disclosure relates to methods for determining the presence, activity, and/or concentrations of certain cancer biomarkers and their use in determining the presence of cancer
Abstract translation: 本公开涉及确定某些癌症生物标志物的存在，活性和/或浓度及其在确定癌症存在中的用途的方法
-
公开(公告)号：WO2011047112A1
公开(公告)日：2011-04-21
申请号：PCT/US2010/052597
申请日：2010-10-14
Applicant: TRAXXSSON, LLC , PUSKAS, Robert , HELD, Douglas
Inventor： PUSKAS, Robert , HELD, Douglas
IPC: G01N33/566 , G01N33/574
CPC classification number: G01N33/57488 , C12Q1/485 , G01N33/6854
Abstract: The present invention relates to a method of detecting the presence of cancer by measuring the level of enzyme activity and autoantibodies in the blood of an individual. In particular the present invention relates to methods for measurement of activated cAMP-dependent protein kinase A (PKA) activity and antibodies to PKA, a kit for activated PKA activity measurement, and the use of the measured levels of these analytes for determining the presence of cancer.
Abstract translation: 本发明涉及通过测量个体血液中酶活性和自身抗体水平来检测癌症存在的方法。 特别地，本发明涉及用于测量活化的cAMP依赖性蛋白激酶A（PKA）活性的方法和PKA抗体，用于活化的PKA活性测量的试剂盒，以及使用测定的这些分析物水平来确定 癌症。
-
公开(公告)号：WO2009126380A8
公开(公告)日：2010-11-04
申请号：PCT/US2009036086
申请日：2009-03-04
Applicant: SINGULEX INC , GOIX PHILIPPE J , PUSKAS ROBERT , TODD JOHN , LIVINGSTON RICHARD A , HELD DOUGLAS , AGEE SARA
Inventor： GOIX PHILIPPE J , PUSKAS ROBERT , TODD JOHN , LIVINGSTON RICHARD A , HELD DOUGLAS , AGEE SARA
IPC: G01N33/53
CPC classification number: G01N33/577 , A61B5/00 , A61B5/0402 , A61B5/412 , A61B5/415 , A61B5/418 , A61B5/7264 , A61B5/7275 , G01N21/6428 , G01N33/582 , G01N33/6863 , G01N33/6869 , G01N33/6872 , G01N33/6887 , G01N33/6896 , G01N33/74 , G01N33/92 , G01N2333/4712 , G01N2333/475 , Y02A90/26 , Y10T436/143333
Abstract: The present invention discloses methods for the detection and monitoring of a condition in a subject using highly sensitive detection of molecules. The invention provides a method for detecting or monitoring a condition in a subject, comprising detecting a first marker in a first sample from the subject and detecting a second marker, wherein the first marker comprises a biomarker, e.g., Cardiac Troponin-I (cTnl) or Vascular Endothelial Growth Factor (VEGF), and wherein the limit of detection of the first marker is less than about 10 pg/ml. The second marker can be a biomarker, physiological marker, a molecular marker or a genetic marker.
Abstract translation: 本发明公开了使用分子的高灵敏度检测来检测和监测受试者的状况的方法。 本发明提供了一种用于检测或监测受试者中的病症的方法，包括检测来自受试者的第一样品中的第一标志物并检测第二标志物，其中第一标记物包含生物标志物，例如心肌肌钙蛋白I（cTn1） 或血管内皮生长因子（VEGF），并且其中第一标记物的检测限小于约10pg / ml。 第二标记可以是生物标志物，生理学标记，分子标记或遗传标记。
-
公开(公告)号：WO2012145382A3
公开(公告)日：2013-02-07
申请号：PCT/US2012034049
申请日：2012-04-18
Applicant: TRAXXSSON LLC , PUSKAS ROBERT , HELD DOUGLAS
Inventor： PUSKAS ROBERT , HELD DOUGLAS
CPC classification number: G01N33/57488 , C12Q1/485 , G01N33/57407 , G01N2333/91205 , G01N2800/52 , G01N2800/56
Abstract: A method for characterizing a carcinoma in a subject. The method comprises assaying a sample of a bodily fluid derived from the subject for extracellular PKA activity and comparing the activity to a reference value. In the assay, a reaction mixture is prepared comprising the previously unfrozen sample, a PKA peptide substrate, a phosphorylation agent, the prepared mixture is incubated, and phosphorylated substrate formed in the incubated mixture is detected. The reference value is the amount of phosphorylated substrate formed in a mixture under equivalent redox conditions for a sample of bodily fluid derived from a population of normal subjects of the same species.
Abstract translation: 用于表征受试者中癌症的方法。 该方法包括测定来源于受试者的体液样品的细胞外PKA活性，并将该活性与参考值进行比较。 在测定中，制备包含先前未冻结的样品，PKA肽底物，磷酸化剂的反应混合物，将所制备的混合物孵育，并检测在培养的混合物中形成的磷酸化底物。 参考值是在等同的氧化还原条件下在来自相同物种的正常受试者群体的体液样品中在混合物中形成的磷酸化底物的量。
-
公开(公告)号：WO2010144358A1
公开(公告)日：2010-12-16
申请号：PCT/US2010/037613
申请日：2010-06-07
Applicant: SINGULEX, INC. , GOIX, Philippe, J. , PUSKAS, Robert , TODD, John , LIVINGSTON, Richard , HELD, Douglas , AGEE, Sara
Inventor： GOIX, Philippe, J. , PUSKAS, Robert , TODD, John , LIVINGSTON, Richard , HELD, Douglas , AGEE, Sara
CPC classification number: G01N33/6869 , G01N33/6893 , G01N2333/32 , G01N2333/47 , G01N2333/4712 , G01N2333/525 , G01N2333/54 , G01N2333/5412 , G01N2333/58 , G01N2800/32 , G01N2800/325 , G01N2800/60
Abstract: Cardiovascular disease, e.g., congestive heart failure, is often first diagnosed after the onset of clinical symptoms, eliminating potential for early intervention. The invention provides a multi-marker immunoassay, including cardiac pathology and vascular inflammation biomarkers, yielding a more sensitive assay for early detection of CHF in plasma. A panel consisting of cardiac pathology (cTnl, BNP) and vascular inflammation (IL-6, TNFα, IL- 17a) biomarkers provided a sensitivity of 94% for association with CHF.
Abstract translation: 心血管疾病，例如充血性心力衰竭，经常在临床症状发作后首先诊断，消除早期干预的可能性。 本发明提供了多标志物免疫测定，包括心脏病理学和血管炎症生物标志物，产生用于血浆中CHF早期检测的更敏感的测定。 由心脏病理学（cTnl，BNP）和血管炎症（IL-6，TNFa，IL-17a）生物标记组成的小组提供了与CHF相关的94％的灵敏度。
-
-
-
-
-
-
-
-
-
Search Results
18
records
(took 0.026 seconds)
